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adenosine-to-inosine conversion at the GluA2 glutamine/arginine (Q/R) site, concomitantly
occur in the same motor neurons of amyotrophic lateral sclerosis (ALS) patients; this
ﬁnding suggests a link between these two ALS-speciﬁc molecular abnormalities. AMPA
receptors containing Q/R site-unedited GluA2 in their subunit assembly are Ca2þ-perme-
able, and motor neurons lacking ADAR2 undergo slow death in conditional ADAR2
knockout (AR2) mice, which is a mechanistic ALS model in which the ADAR2 gene is
targeted in cholinergic neurons. Moreover, deﬁcient ADAR2 induced mislocalization of
TDP-43 similar to TDP-43 pathology seen in the sporadic ALS patients in the motor neurons
of AR2 mice. The abnormal mislocalization of TDP-43 speciﬁcally resulted from activation
of the Ca2þ-dependent serine protease calpain that speciﬁcally cleaved TDP-43 at the
C-terminal region, and generated aggregation-prone N-terminal fragments. Notably, the
N-terminal fragments of TDP-43 lacking the C-terminus were demonstrated in the brains
and spinal cords of ALS patients. Because normalization of either the Ca2þ-permeability of
AMPA receptors or the calpain activity in the motor neurons normalized the subcellular
localization of TDP-43 in AR2 mice, it is likely that exaggerated calpain-dependent TDP-43
fragments played a role at least in the initiation of TDP-43 pathology. Elucidation of the
molecular cascade of neuronal death induced by ADAR2 downregulation could provide a
new speciﬁc therapy for sporadic ALS. In this review, we summarized the work from our
group on the role of inefﬁcient GluA2 Q/R site-RNA editing and TDP-43 pathology inr B.V. This is an open access article under the CC BY-NC-ND license
.
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b r a i n r e s e a r c h 1 5 8 4 ( 2 0 1 4 ) 2 8 – 3 8 29sporadic ALS, and discussed possible effects of inefﬁcient ADAR2-mediated RNA editing in
general.
This article is part of a Special Issue entitled RNA Metabolism 2013.
& 2013 The Authors. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. ALS and causative genes
Amyotrophic lateral sclerosis (ALS) is the most common
adult-onset motor neuron disease affecting healthy middle-
aged individuals. The disease course is rapidly progressive,
and the eventual respiratory muscle weakness results in
death within a few years of onset. More than 90% of ALS
cases are sporadic in which the cause of ALS is largely
unknown. The remaining cases of ALS are familial (approxi-
mately 5–10% of all ALS cases), in approximately half of these
cases mutations in several genes have been demonstrated. At
present, more than 20 different mutant genes are known to
cause familial ALS (Ferraiuolo et al., 2011; Rademakers and
van Blitterswijk, 2013), including SOD1 (Rosen et al., 1993),
chromosome 9 open reading frame 72 (C9ORF72) (DeJesus-
Hernandez et al., 2011; Renton et al., 2011), TAR DNA-binding
protein (TARDBP) (Gitcho et al., 2008; Kabashi et al., 2008;
Sreedharan et al., 2008; Van Deerlin et al., 2008; Yokoseki
et al., 2008), Fused in sarcoma (FUS) (Kwiatkowski et al., 2009;
Vance et al., 2009). These genes account for about 50% of all
familial ALS cases (Ferraiuolo et al., 2011), while only a small
percentage of sporadic ALS cases had mutations found in
these genes. Therefore, it is likely that multiple different
molecular mechanisms underlie sporadic ALS and each
familial ALS that are associated with different individual
causative genes; TDP-43 is a pathological hallmark of the
majority of ALS patients, and both TDP-43 pathology and
inefﬁcient editing of the GluA2 Q/R site occur concomitantly
in many of the motor neurons of patients with sporadic ALS
(Aizawa et al., 2010). In TARDBP-associated ALS, although
TDP-43 pathology is the pathological characteristics as in
sporadic ALS that carry wild-type TARDBP gene, ADAR2
downregulation has not been demonstrated. Likewise,
neither of these two abnormalities were observed in the
motor neurons of SOD1-associated ALS patients or SOD1
transgenic animals (Kawahara et al., 2006; Mackenzie et al.,
2007; Robertson et al., 2007; Tan et al., 2007). Therefore,
elucidation of pathogenic mechanisms speciﬁc for sporadic
ALS and individual familial ALS cases will be necessary to
develop new gene-targeting therapeutic strategies.2. Abnormal RNA editing and ADAR2 in
sporadic ALS motor neurons
GluA2 (previously called GluR2 or GluR-B) is a subunit of the
L-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptor and pre-mRNA of GluA2 is normally subjected to
RNA editing at the glutamine/arginine (Q/R) site. The adeno-
sine at the Q/R site of GluA2 pre-mRNA is converted to
inosine (A-to-I conversion) and the genomic CAG codon for
Q is converted to a CIG codon in mRNA, and CIG is read asCGG, which is a codon for R during translation. Additionally,
because the A-to-I conversion invariably occurs at the Q/R
site, all of the GluA2 mRNA expressed in neurons is edited to
an R at this site (GluA2R) (Kawahara et al., 2004; Sommer
et al., 1991; Takuma et al., 1999).
In the spinal motor neurons of the majority of sporadic ALS
patients, RNA editing of GluA2 is inefﬁcient at the glultamine/
arginine (Q/R) site, and abnormal Q/R site-unedited GluA2
(GluA2Q) is expressed in approximately half of remaining motor
neurons in an individual patient (Hideyama et al., 2012b;
Kawahara et al., 2004; Takuma et al., 1999). The expression of
GluA2Q in motor neurons has been demonstrated in the
majority of sporadic ALS patients so far examined (430 cases)
irrespective of the difference in clinical manifestations
(Hideyama et al., 2012b), whereas motor neurons from control
subjects and patients with other diseases, including other motor
neurons diseases, including spinal and bulbar muscular atrophy
and SOD1-associated ALS do not express GluA2Q (Kawahara
et al., 2006).
Functional AMPA receptors are homo- or hetero-tetramers
of four subunits called GluA1–GluA4. The nucleotide
sequence in the genomic Q/R site is CAG (a codon for Q) in
all of AMPA receptor subunits, and only GluA2 expresses R at
the Q/R site resulting from A-to-I conversion (Seeburg, 2002).
AMPA receptors are either Ca2þ-permeable or -impermeable,
which is determined by whether the AMPA receptor has
GluA2R in its subunit or not; only the AMPA receptors having
GluA2R is Ca2þ-impermeable, whereas those composed of
only Q/R site-unedited subunits, including GluA2Q are Ca2þ-
permeable (Seeburg, 2002). A-to-I conversion at the GluA2 Q/R
site occurs in all GluA2 expressed in neurons and virtually all
neurons in the mammalian brain express only GluA2R
(Seeburg, 2002). Additionally, failure of Q-to-R conversion at
this site produces Ca2þ-permeable AMPA receptors that
results in increased excitation of neurons, which has been
shown to culminate in fatal status epilepticus in mice (Brusa
et al., 1995; Feldmeyer et al., 1999; Higuchi et al., 2000).
Adenosine deaminase acting on RNA 2 (ADAR2) speciﬁcally
catalyzes the A-to-I conversion at the Q/R site of GluA2 pre-
mRNA (Higuchi et al., 1993, 2000). In mammals, there are three
structurally related members (ADAR1, ADAR2 and ADAR3) in
the ADAR family. ADARs possess two or three double strand
RNA binding domains in the N-terminal region and one deami-
nase domain in the C-terminal region (Hogg et al., 2011).
Although ADAR1 and ADAR2 actively catalyze A-to-I conversion
with different substrate spectra, ADAR3 that is speciﬁcally
expressed in the brain, predominantly in the white matter,
exhibits no editing activity in either naturally occurring or
artiﬁcial substrates (Chen et al., 2000; Melcher et al., 1996).
In accordance with these studies on mammalian brains,
a recent study demonstrated that the expression levels of
ADAR2, but not of ADAR1 or ADAR3, were signiﬁcantly
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compared to normal and disease control cases (Hideyama
et al., 2012b). Previous studies on gene expression in a global
scale has not demonstrated the reduction of ADAR2 gene
expression in ALS motor neurons (Jiang et al., 2005), presum-
ably due to the technical reasons. The reduction of ADAR2
expression was extensive in ALS motor neurons expressing
GluA2Q, and mild but signiﬁcant in those expressing only
GluA2R (Hideyama et al., 2012b). These results indicate that
ADAR2 downregulation is a selective, profound and disease-
speciﬁc pathological change in motor neurons from sporadic
ALS patients.
Recently, by using global genome wide and RNA sequen-
cing analysis, it is now recognized that ADAR2 is involved in
the editing of a large number of RNAs including GluA2
(Cattenoz et al., 2013; Li et al., 2009; Maas et al., 2011; Peng
et al., 2012; Zhu et al., 2013). The reduction of ADAR2 in motor
neurons from ALS patients may induce various defects,
including the potential alteration in the role for RNA splicing
(Solomon et al., 2013) and control of neuronal excitability
(Li et al., 2013). Furthermore, hnRNP A2/B1, known as an
enhancer of RNA editing (Garncarz et al., 2013), was recently
reported to link to ALS and frontotemporal dementia (FTD)
(Kim et al., 2013). Although the functional signiﬁcance is not
clear, there is a report regarding association of ALS and
abnormal editing of the glutamate transporter EAAT2, of
which downregulation was previously discussed for the
pathogenic role in ALS (Flomen and Makoff, 2011). These
reports may also suggest the role of altered RNA editing in the
pathogenesis of ALS.3. Abnormal RNA editing and motor neuron
death
Pathogenic roles of inefﬁcient RNA editing at the GluA2 Q/R
site for sporadic ALS have been demonstrated in the motor
neuron-selective conditional ADAR2 knockout (AR2) miceWild Type
Fig. 1 – TDP-43 is mislocalized in motor neurons lacking ADAR2
neurons of wild-type mice exhibiting nuclear TDP-43 (green). (B
AR2 mouse. Numerous TDP-43-positive aggregates in the cytopla
the nucleus (blue) of motor neurons. TOPRO-3 is a cellular make
indicating abnormal cytoplasmic inclusions positive for phosphcarrying ﬂoxed ADAR2 alleles that are targeted by Cre
expressed under the control of vesicular acetylcholine trans-
porter (VAChT) promotor (Hideyama et al., 2010). These AR2
mice displayed a slow and progressive motor dysfunction
attributable to loss of ADAR2-lacking motor neurons and
their neuromuscular motor units. Because the expression of
GluA2R by genetic engineering of the endogenous GluA2 gene
rescued ADAR2-lacking motor neurons from death in AR2
mice, these results indicate that the death of motor neurons
was caused by a Ca2þ-permeable AMPA receptor-mediated
mechanism resulting from inefﬁcient RNA editing at the
GluA2 Q/R site (Hideyama et al., 2010). In heterozygous AR2
(AR2H) mice in which one ADAR2 gene allele was ablated in
motor neurons, the motor neurons with reduced ADAR2
expressed GluA2Q mRNA, although to a lesser extent com-
pared to ADAR2-lacking motor neurons in homozygous AR2
mice, and underwent a slow death when examined at 12
months of age (Hideyama and Kwak, 2011).
Taken together, expression of GluA2Q, even if it is a small
proportion of all AMPA receptors, is not favorable for the
survival of motor neurons in mice and expression of ADAR2
at a level sufﬁcient to edit all of the GluA2 mRNA rather than
the expression level of ADAR2 per se is the critical factor for
motor neuron survival. The critical role of GluA2 Q/R site-
editing in neuronal death in mice indicates the pathogenic
role of GluA2Q expression in ALS motor neurons (Hideyama
et al., 2010). Therefore, insufﬁcient levels of ADAR2 that leads
to the expression of GluA2Q are a likely cause of death of
motor neurons in sporadic ALS.4. TDP-43 and RNA editing
The abnormal processing and mislocalization of TAR DNA-
binding protein-43 (TDP-43) in motor neurons is known as a
pathological hallmark of sporadic ALS (Arai et al., 2006;
Neumann et al., 2006) (Fig. 1). TDP-43 is a nuclear protein
involved in the regulation of RNA processing (Buratti andAR2 
Sporadic ALS
in conditional ADAR2 knockout mice (AR2): (A) spinal motor
) Immunohistochemistry for TDP-43 in the spinal cord of an
sm (arrow) and a reduction or absence (asterisk) of TDP-43 in
r (blue). (C) TDP-43 pathology in patients with sporadic ALS,
orylated TDP-43.
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Gendron and Petrucelli, 2011; Iguchi et al., 2009; Johnson
et al., 2009; Nonaka et al., 2009; Polymenidou et al., 2011;
Sephton et al., 2011; Tollervey et al., 2011; Zhang et al., 2009).
TDP-43 pathology was also observed in pathological brain
regions of Frontotemporal Lobar Degeneration (FTLD) and
Alzheimer's disease (Wilson et al., 2011) in which RNA editing
was efﬁcient, suggesting that there were several different
causes for TDP-43 pathology. TDP-43 pathology consists of a
combination of molecular abnormalities including absence
from the nucleus, where it normally resides, mislocalization
to abnormal cytoplasmic inclusions and abnormal fragmen-
tation and hyperphosphorylation (Arai et al., 2006; Chen-
Plotkin et al., 2010; Hasegawa et al., 2008; Neumann et al.,
2006).
TDP-43 pathology is believed to be initiated from the
formation of small aggregates that are generated by fragmen-
tation of TDP-43 in the cytoplasm, which serve as seeds for
large inclusions that increase in size with sequestration of
full-length and fragments of TDP-43 (Chen-Plotkin et al., 2010).
Although protease-dependent cleavage of TDP-43 is likely a
trigger for TDP-43 pathology, neither the proteases involved
nor the mechanism of protease activation are known. TDP-43
pathology is rarely, if ever, observed in the motor neurons
of patients who have SOD1-associated ALS or in SOD1 Tg
animals (Mackenzie et al., 2007; Robertson et al., 2007;
Tan et al., 2007). Moreover, inefﬁcient RNA editing at the
GluA2 Q/R site in motor neurons of sporadic ALS does not
occur in SOD1 Tg rats (Aizawa et al., 2010; Kawahara et al.,
2006). The difference, in light of TDP-43 processing and
ADAR2 regulation, between these two ALS model lines
suggests a mechanistic difference between SOD1-associatedFig. 2 – The cascades of RNA editing at the GluA2 Q/R site and ab
that TDP-43 processing abnormality induces deﬁcient ADAR2. (B
inﬂuences the generation of TDP-43 pathology.ALS and sporadic ALS. Notably, disease-speciﬁc abnormalities
of both ADAR2 underactivity and TDP-43 pathology were
concomitantly observed in the same motor neurons of
sporadic ALS patients, suggesting a molecular link between
these two molecular abnormalities (Aizawa et al., 2010).
Furthermore, these two molecular abnormalities in motor
neurons were observed not only in sporadic ALS patients but
also in elderly humans and mice (Geser et al., 2010; Hideyama
et al., 2012a), providing evidence that there is an intimate
molecular linkage between both (Fig. 2).
Experiments using various lines of cultured cells demon-
strated that none of TDP-43 overexpression, TDP-43 knockdown,
TDP-43 C-terminal fragments or TDP-43 mutations, changed the
expression levels of ADAR2 (Yamashita et al., 2012b). These
results suggest that the abnormal processing of TDP-43 is not
an upstream event of inefﬁcient GluA2 Q/R site RNA editing in
the motor neurons of sporadic ALS patients.
The downregulation of ADAR2 in motor neurons of sporadic
ALS patients occurred before RNA editing at the GluA2 Q/R site
was inefﬁcient, and TDP-43 pathology was generated only in
motor neurons that have very low ADAR2 expression (Hideyama
et al., 2012b). ADAR2-lacking motor neurons in AR2 and AR2H
mice underwent death via a Ca2þ-permeable AMPA receptor-
mediated mechanism (Hideyama et al., 2010; Hideyama and
Kwak, 2011), and exhibited loss of TDP-43 from the nucleus and
TDP-43-containing abnormal aggregates in the cytoplasm (Figs. 1
and 3) (Yamashita et al., 2012a). In vitro calpain assay demon-
strated that TDP-43 was speciﬁcally cleaved by calpains. Clea-
vage of TDP-43 was inhibited by endogenous and exogenous
calpain inhibitors both in vivo and in vitro and when the AR2mice
were engineered to express Ca2þ-impermeable AMPA receptors
with GluA2R in the absence of ADAR2 by crossing with GluR-BR/Rnormal TDP-43 processing: (A) illustration of the hypothesis
) Illustration of the hypothesis that ADAR2 underactivity
WT
AR2
AR2H
ADAR2 TDP-43 Merge
Fig. 3 – TDP-43 pathology and ADAR2 in spinal motor neurons (AHCs) (AR2 and AR2H). Immunoﬂuorescence assays revealed
that ADAR2 (red) and TDP-43 (green) both localize to the nucleus in control AHCs.TDP-43 immunoreactivity was absent in
AHCs that lack ADAR2 in AR2 mice (arrow). AHCs with low immunoreactivity for ADAR2 showed TDP-43 immunoreactivity in
the cytoplasm and TDP-43-positive cytoplasmic aggregates in heterozygous AR2 mice (AR2H) (arrow). TOPRO-3 is a cellular
maker (blue).
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Fig. 4 – Aggregation of calpain-dependent TDP-43 N-terminal fragments: (A) the proportion of cells that have aggregates among
those exhibiting GFP signals was calculated. The larger calpain-dependent TDP-43 fragments (1–286 and 1–324) induced
cytoplasmic aggregations in a larger number of cells than the full-length TDP-43 (1-414) or the small calpain-dependent TDP-43
fragment (1–243). (B) Examples of cells 72 h after transfection with the GFP-TDP-43 fragment (1–324). TDP-43-positive aggregates
formed in the nucleus and cytoplasm of culture cells transfected with the GFP-TDP-43 fragment (1–324).
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TDP-43 cleavage and mislocalization in the neurons were exag-
gerated in calpastatin knockout mice. These results indicated
that the fragmentation and abnormal localization of TDP-43
observed in AR2 and AR2H mice were dependent on the
activation of calpain through Ca2þ-permeable AMPA receptors
(Yamashita et al., 2012a).
The Ca2þ-dependent serine protease calpain cleaved TDP-43
at several positions in the C-terminal region and the resulting
N-terminal fragments were prone to aggregation (Fig. 4)
(Yamashita et al., 2012a). In the brains and spinal cords of
ALS patients, calpain is more active compared to normal
control subjects and calpain-dependent TDP-43 fragments were
demonstrated in the lysates and sarkosyl-insoluble fraction,
suggesting that the calpain-dependent cleavage of TDP-43 may
be involved in the pathogenesis of TDP-43 pathology of ALS
motor neurons the same as observed in AR2 mouse motor
neurons (Yamashita et al., 2012a).
There were many reports indicating that the TDP-43 clea-
vage was caused by caspase-3 (Dormann et al., 2009; Igaz et al.,
2009; Zhang et al., 2007) and loss of function of the progranulin
has been suggested to lead to caspase-3 activation. The
caspase-3-dependent proteolysis of the TDP-43 generated
C-terminal fragments (CTFs) but researchers demonstrated
the presence of TDP-43 CTFs that were generated by caspase-
dependent and -independent cleavage (Herskowitz et al., 2012;
Nishimoto et al., 2009; Nonaka et al., 2009) and fragmentsconsistent with those generated by cleavage with both calpain
and caspase-3 was demonstrated in sporadic FTLD-ALS brain
and spinal cord extracts (Yamashita et al., 2012a). These
observations suggest that caspase-3-dependent cleavage of
TDP-43 may participate in TDP-43 pathology by cleaving the
full-length and calpain-dependent fragments of TDP-43 into
aggregation-prone fragments. However, caspase-3 cleaved TDP-
43 far less effectively than calpain (Yamashita et al., 2012a) and
caspase-3 was activated after the activation of calpain in the
brains of excitotoxic model animals (Takano et al., 2005),
suggesting the minor participation of caspases in TDP-43
compared to calpains.
Taken together, these results indicate that the calpain-
dependent cleavage of TDP-43 plays a crucial role in ALS
pathology (Fig. 5), although the link between the formation of
TDP-43 aggregation and cell death is unknown.5. TARDBP-associated ALS and Calpain
TDP-43 pathology appears in the motor neurons of patients
with ALS associated with mutations in the TARDBP gene as
well as sporadic ALS patients who express wild-type TDP-43
(Arai et al., 2006; Chen-Plotkin et al., 2010; Hasegawa et al.,
2008; Lagier-Tourenne et al., 2010; Neumann et al., 2006).
Although an increased vulnerability of cultured cells expres-
sing mutant TDP-43 compared to those expressing wild-
Fig. 5 – Schematic illustration of the molecular mechanism underlying TDP-43 pathology in sporadic ALS motor neurons:
(A) Normal neurons. (B) Motor neurons of sporadic ALS patients: downregulation of ADAR2-failure of RNA editing at the Q/R site of
GluA2 pre-mRNA-expression of calcium-permeable AMPA receptors (AMPA R) at the synaptic spines. (C) An increase of cytoplasmic
calcium concentration. Activation of calpain. (D) Cleavage of TDP-43 by activated calpain-aggregation of TDP-43 fragments-
sequestration of TDP-43 that shuttles between the nucleus and the cytoplasm into the aggregates, resulting in the large inclusions.
Other Ca
channels 
GluA2-lacking
AMPAR
GluA2-containing
AMPAR
TARDBP-associated ALS
Other class of Neurons Motor Neuron
Fig. 6 – Schematic illustration of the molecular mechanism underlying TARDBP-ALS motor neuron and other class of neurons.
The expression of ADAR2 is normal, and Q/R site-edited GluA2 is expressed with normal activation of calpain in TARDBP-ALS.
In TARDBP-ALS motor neurons, calpain activity is higher than in other classes of neurons presumably due to the higher
expression level of GluA2-lacking Ca2þ-permeable AMPAR. The increased vulnerability of mutant TDP-43 to calpain-mediated
cleavage in motor neurons with physiologically high calpain activity generates more abundant highly aggregation-prone
fragments in the motor neurons than in other classes of neurons of TARDBP-ALS patients.
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Sreedharan et al., 2008), molecular mechanisms whereby
mutant and wild-type TDP-43 exhibit similar pathology have
not been elucidated. Recent ﬁnding that ALS-linked mutant
TDP-43 (A315T, M337V) was more effectively cleaved by
calpains than wild-type TDP-43 suggested that increased
liability to calpain-dependent cleavage was involved in the
TDP-43 pathology observed in the motor neurons of TARDBP-
ALS patients. In addition, the increased susceptibility of
mutant TDP-43 to calpain cleavage enables to explain the
ﬁnding that patients who have mutations in the TARDBP gene
exhibit an ALS phenotype but not, or at least very infre-
quently, a frontotemporal dementia (FTD) phenotype (Chen-
Plotkin et al., 2010). Ca2þ inﬂux through the AMPA receptors is
known to be greater in the spinal motor neurons than in the
dorsal horn neurons in a primary culture of spinal cord
neurons (Carriedo et al., 1996), and calpain activity in the
spinal motor neurons was greater than in other neurons,
such as cortical and dorsal horn neuron of autopsied human
subjects free from neurological diseases (Yamashita et al.,
2012a). Spinal motor neurons express relatively low levels of
GluA2 compared to other classes of neurons in humans and
rodents (Carriedo et al., 1996; Kawahara et al., 2003; Sun et al.,
2005), indicating that more abundant AMPA receptors lacking
GluA2 resulted in higher Ca2þ inﬂux through AMPA receptors
and calpain activity in motor neurons than in other class of
neurons (Fig. 6). These lines of evidence suggest that a greater
amount of TDP-43 fragments would be generated in the motor
neurons in which Ca2þ-permeable AMPA receptors lacking
GluA2 are abundantly expressed, and the motor neuron-prone
generation of TDP-43 pathology results in ALS phenotype in
TARDBP patients (Chen-Plotkin et al., 2010; Lagier-Tourenne
et al., 2010). Therefore, although the role of calpain is critical
in TDP-43 pathology, different mechanisms may enhance
calpain-dependent TDP-43 cleavage between sporadic ALS and
TARDBP-ALS. In sporadic ALS, activation of calpain by increased
Ca2þ inﬂux through the upregulation of Ca2þ-permeable AMPA
receptors containing GluA2Q enhanced TDP-43 cleavage,
whereas the increased vulnerability of mutant TDP-43 to
calpain-mediated cleavage generates abnormal TDP-43 frag-
ments in TARDBP-ALS motor neurons where calpain activity
is higher than in other classes of neurons presumably due to
the higher expression level of GluA2-lacking Ca2þ-permeable
AMPA receptors.
In motor neurons of both sporadic ALS and TARDBP-asso-
ciated ALS, highly aggregation-prone calpain-dependent TDP-43
fragments generated cytoplasmic inclusions to which nucleo-
cytoplasm shuttling TDP-43 was sequestered and disappeared
from the nucleus (Figs. 5 and 6) (Yamashita et al., 2012a). These
results suggest that the same pathology would be generated
from different mechanisms and that we should be prudent to
assess the pathological hallmark as a disease hallmark.6. TDP-43 pathology in other neurological
diseases
TDP-43 pathology is observed not only in ALS motor
neurons and FTLD-TDP cortical neurons but also in patho-
logical brain regions of various other neurological diseases,including Alzheimer's disease (Wilson et al., 2011) and
traumatic brain injury (McKee et al., 2010), as well as in
the CNS of animals exposed to various adverse conditions,
including sciatic axotomies (Moisse et al., 2009) and brain
ischemia (Kanazawa et al., 2011). Because Ca2þ dysregulation
and calpain activation have been reported in various diseases
(Lopatniuk and Witkowski, 2011), calpain activated via various
abnormal Ca2þ signaling pathways could play important
roles for TDP-43 pathology. In fact, age-associated calpain
activation may be involved in the mechanism underlying
mislocalization of TDP-43 from the nucleus to the cytoplasm
that is observed in the cortical neurons of normal elderly
people (Geser et al., 2010) and motor neurons of aged mice
(Hideyama et al., 2012a). Scrutiny of the roles of various
pathways causing Ca2þ dysregulation in the pathological con-
ditions in TDP-43 may improve our knowledge about the
mechanism generating TDP-43 pathology in various neurolo-
gical diseases other than ALS.7. Conclusion and future directions
In this review, we summarized the evidence indicating the
role of inefﬁcient RNA editing in the pathogenesis of spora-
dic ALS. These molecular abnormalities cause death of
motor neurons and TDP-43 pathology in the motor neurons
of the conditional ADAR2 knockout mouse, a mechanistic
model of sporadic ALS. However, we still do not know how
the mislocalization of TDP-43 leads motor neurons to death
or whether the mislocalization of TDP-43 occurs in the death
cascade or merely an associated phenomenon observed
downstream of ADAR2 downregulation.
Another unresolved question is why ADAR2 is down-
regulated in ALS motor neurons. Recent studies on dysfunc-
tion of some ALS associated genes seem to provide us a clue
for the mechanism. ALS-linked genes encode proteins
involved in RNA processing, and using iPS cells, ﬁbroblasts
and brains from patients carrying expansion of GGGGCC
repeat in C9orf72 gene, an ALS-linked gene, several reports
showed formation of abnormal RNA foci in which some RNA-
binding proteins, including ADARB2 (or ADAR3) protein, a
member of the RNA editing enzyme family, were demon-
strated (Donnelly et al., 2013; Gendron et al., 2013; Lagier-
Tourenne et al., 2013; Sareen et al., 2013; Zu et al., 2013).
Furthermore, nuclear-enriched abundant transcript 1_2
(NEAT1_2), a long non-coding RNA, was demonstrated to
bind to TDP-43 and FUS/TLS (products of an ALS-linked gene)
in the spinal motor neurons of ALS patients (Nishimoto
et al., 2013). These lines of evidence suggest that abnormal
RNA-associated foci generated by dysfunction of ALS-
associated genes may act as a scaffold of RNAs and RNA
binding proteins in the nuclei of ALS motor neurons, thereby
modulating the gene expression that is critical for neuronal
survival (Donnelly et al., 2013; Kwak and Kawahara, 2005).
Because ADAR2 downregulation is one death-causing mole-
cular abnormalities demonstrated in ALS motor neurons,
scrutiny for the effects of sequestration of gene-regulatory
molecules on ADAR2 gene expression may provide us a clue
for the mechanism underlying the ADAR2 downregulation
and ALS pathogenesis.
b r a i n r e s e a r c h 1 5 8 4 ( 2 0 1 4 ) 2 8 – 3 836Because of the close association of the cascade downstream
of ADAR2 downregulation to ALS pathogenesis, enhancement
of deﬁcient ADAR2 in the motor neurons to a level sufﬁcient to
edit the GluA2 Q/R site may be a logical new therapy for
sporadic ALS and the normalization of TDP-43 nuclear localiza-
tion would be a biomarker for the therapeutic effects in the
model animals (Yamashita et al., 2013).Acknowledgments
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